ANX1502 found safe in Phase 1 trial with healthy volunteers
Twice-daily dosing of ANX1502, Annexon Biosciences’ experimental oral therapy for autoimmune conditions such as cold agglutinin disease (CAD), reached the desired levels in the blood of healthy volunteers who took part in a Phase 1 clinical trial. Taken by mouth as a liquid suspension, ANX1502 was well tolerated,…